Improving the Quality of Near-Patient Blood Glucose Measurement

Author(s):  
R H Pollard
2006 ◽  
Vol 8 (3) ◽  
pp. 347-357 ◽  
Author(s):  
John M. Baum ◽  
Nanette M. Monhaut ◽  
Donald R. Parker ◽  
Christopher P. Price

Author(s):  
A G Rumley

The quality of near-patient blood glucose measurement was audited in our hospitals in 1990, when a diversity of glucose meters were in use, by sending three samples of unknown (to the meter user) concentration to each user and collecting and analysing the results produced. The overall performance was unsatisfactory with a mean coefficient of variation (CV) of 23·5%. A scheme involving training, quality control and external quality assurance was introduced in 1993 based on the Bayer Glucometer II meter. This meter was used exclusively throughout our hospitals. Data from the quality assurance scheme showed that the overall CV fell initially to 14–16% and then settled at about 10–12% for the following 2 years. Unacceptable results (those more than two standard deviations from the mean) were 8–12% of the total. A new meter was introduced in 1995 (the Bayer Glucometer 4) which had the advantages of ‘no-wipe’ and automatic timing technology and in the subsequent year overall CV fell to 5–6% and has remained at this level. The frequency of unacceptable results fell to 5–7%. The improved precision figures encouraged us to change criteria for acceptability to mean ±15%. Using these criteria the level of unacceptable results is now 1–2%. This study shows that introducing training, quality control procedures, a quality assurance scheme and improved meter technology all backed by laboratory expertise can produce significant improvement in the quality of near patient blood glucose measurement.


1999 ◽  
Author(s):  
Airat K. Amerov ◽  
Kye Jin Jeon ◽  
Yoen-Joo Kim ◽  
Gilwon Yoon

2017 ◽  
Vol 16 (2) ◽  
pp. 59-64
Author(s):  
Kh. A. Kurdanov ◽  
A. D. Elbaev ◽  
A. D. Elbaeva ◽  
R. I. Elbaeva

2020 ◽  
Vol 11 ◽  
Author(s):  
Marcia Roeper ◽  
Roschan Salimi Dafsari ◽  
Henrike Hoermann ◽  
Ertan Mayatepek ◽  
Sebastian Kummer ◽  
...  

ObjectiveAim was to identify hypotheses why adverse neurodevelopment still occurs in children with transient or persistent hyperinsulinism despite improvements in long-term treatment options during the last decades.Material and MethodsA retrospective review of 87 children with transient (n=37) or persistent congenital hyperinsulinism (CHI) (n=50) was conducted at the University Children’s Hospital Duesseldorf, Germany. Possible risk factors for neurodevelopmental sequelae due to hypoglycemia were analyzed with a focus on the first days after onset of disease.ResultsMedian age at follow-up was 7 years (IQR 8). Adverse neurodevelopmental outcome was seen in 34.5% (n=30) of all CHI patients. Fifteen had mildly abnormal neurodevelopment and 15 had a severe hypoglycemic brain injury. In univariate analysis, mildly abnormal neurodevelopment was associated with the diagnosis of persistent CHI (odds ratio (OR) 8.3; p=0.004) and higher birth weight (mean difference 1049 g; p<0.001). Severe hypoglycemic brain injury was associated with the diagnosis of persistent CHI (OR 5.1; p=0.013), being born abroad (OR 18.3; p<0.001) or in a lower-level maternity hospital (OR 4.8; p=0.039), and of note history of hypoglycemic seizures (OR 13.0; p=<0.001), and a delay between first symptoms of hypoglycemia and first blood glucose measurement/initiation of treatment (OR 10.7; p<0.001). Children with severe hypoglycemic brain injury had lower recorded blood glucose (mean difference -8.34 mg/dl; p=0.022) and higher birth weight than children with normal development (mean difference 829 g; p=0.012). In multivariate binary logistic regression models, lowest blood glucose <20 mg/dl (OR 134.3; p=0.004), a delay between initial symptoms and first blood glucose measurement/initiation of treatment (OR 71.7; p=0.017) and hypoglycemic seizures (OR 12.9; p=0.008) were positively correlated with severe brain injury. Analysis showed that the odds for brain injury decreased by 15% (OR 0.85; p=0.035) if the blood glucose increased by one unit.ConclusionWhile some risk factors for adverse outcome in CHI are not influenceable, others like lowest recorded blood glucose values <20 mg/dl, hypoglycemic seizures, and insufficiently—or even untreated hypoglycemia can be avoided. Future guidelines for management of neonatal hypoglycemia should address this by ensuring early identification and immediate treatment with appropriate escalation steps.


Sign in / Sign up

Export Citation Format

Share Document